The Guangdong Provincial Key Laboratory of Cardiovascular Drug R and D Enterprises, Shenzhen Salubris Pharmaceuticals Co., Ltd., Shenzhen, Guangdong Province, China.
2 papers in the library · 1 citation · publishing 2024-2026
A novel formulation combining deuterated dextromethorphan (SAL0114) with bupropion showed twice the metabolic stability of standard dextromethorphan in both laboratory and mouse tests, and bupropion further increased its exposure by 2.4 times. The combination demonstrated superior antidepressant and synergistic effects in mouse and rat models compared with the non-deuterated dextromethorphan-bupropion combination, while maintaining the same in vitro activity. Deuteration did not alter the compound's activity but improved its stability, potentially reducing neurologic side effects from metabolites and allowing lower bupropion doses. Clinical studies are needed to confirm these preclinical findings.
Tinnitus, the perception of sound without an external source, lacks effective treatments. Psilocybin, a psychedelic, shows promise by activating 5-HT2A receptors, boosting glutamate release, and upregulating BDNF, which increases dendritic spine density and synaptic proteins in the hippocampus and prefrontal cortex, restoring neural plasticity. This review connects these neuroplasticity mechanisms to tinnitus-related neural changes, highlighting psilocybin's regulatory effects on excitatory (glutamate, dopamine) and inhibitory (GABA) neurotransmitters and their receptors, suggesting a novel therapeutic pathway.